Inpoza Capsule 50 mg is an oral drug used to treat metastatic breast cancer, ovarian cancer, and other types of cancer. It belongs to a group of medications called PARP inhibitors. Inpoza Capsule 50 mg works by blocking an enzyme called poly (ADP-ribose) polymerase (PARP). This enzyme is involved in DNA repair in cancer cells, and blocking it can slow cancer cell growth. Inpoza Capsule 50 mg is approved by the US Food and Drug Administration (FDA) for people with ovarian cancer who have been previously treated with platinum-based chemotherapy.
Inpoza Capsule 50 mg is used to treat adults with advanced ovarian cancer who have had two or more prior chemotherapy treatments, metastatic breast cancer in people with inherited mutations (BRCA-positive) who have progressed after chemotherapy, metastatic castration-resistant prostate cancer with DNA repair defects, and other types of cancer. Inpoza Capsule 50 mg is also being studied in the treatment of other types of cancer.
Inpoza Capsule 50 mg is an inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP). PARP is involved in DNA repair in cancer cells. Inpoza Capsule 50 mg blocks PARP and this prevents DNA repair in the cancer cells, leading to their death. By targeting only cancer cells, olaparib can reduce the side effects that accompany chemotherapy.
The exact time frame for olaparib to start working can vary from person to person, but generally it takes several weeks for the effects of olaparib to become evident. It may also take several weeks for the tumor to start shrinking.
Inpoza Capsule 50 mg is generally well absorbed after oral administration. The bioavailability of the drug is approximately 45%. Peak concentrations are reached after 6 hours.
Inpoza Capsule 50 mg is eliminated primarily through the kidneys. It has a plasma half-life of about 17 hours.
The recommended dose of olaparib is 400 mg taken orally twice daily. Patients should take the medication with a meal. The dose can be reduced in people with certain conditions or if significant side effects occur.
Inpoza Capsule 50 mg is taken orally with a meal. Patients should take the medication as prescribed by their doctor. If a dose is missed, it should be taken as soon as possible. If it is almost time for the next dose, the missed dose should be skipped.
Common side effects of olaparib include nausea, tiredness, vomiting, headache, anemia, and constipation. Other serious side effects may include liver damage, difficulty breathing, and seizures. Patients should contact their doctor right away if they experience any of these symptoms.
Inpoza Capsule 50 mg can be toxic if too much is taken, either as a single dose or over a period of time. The most commonly reported symptoms of overdose include nausea, vomiting, and difficulty breathing. Patients who take more than the recommended dose of olaparib should contact their doctor right away for treatment.
Patients should tell their doctor about all the medications they are taking, including vitamins and herbal supplements, as they may interact with olaparib. Patients should also let their doctor know if they have any existing medical conditions, such as liver or kidney disease, as this may affect how olaparib is metabolized in the body. Women who are pregnant or breastfeeding should not take olaparib.
Inpoza Capsule 50 mg may interact with other medications, including other cancer treatments, antibiotics, antifungals, anticonvulsants, and medications that affect the liver. Patients should tell their doctor about all the medications they are taking, including vitamins and herbal supplements, before starting olaparib.
Patients with certain diseases, such as liver or kidney disease, may be at increased risk of negative reactions when taking olaparib. Patients should talk to their doctor before taking olaparib if they have any existing medical conditions.
Inpoza Capsule 50 mg can interact with other medications. This includes other cancer treatments, antibiotics, antifungals, anticonvulsants, and medications that affect the liver. Patients should tell their doctor about all the medications they are taking, including vitamins and herbal supplements, before starting olaparib.
Inpoza Capsule 50 mg may interact with certain foods. In particular, grapefruit and grapefruit juice may increase the levels of olaparib in the body. It is recommended that patients avoid grapefruit and grapefruit juice while taking olaparib.
Inpoza Capsule 50 mg is not recommended for use during pregnancy. Women who are pregnant or planning to become pregnant should talk to their doctor before taking olaparib.
It is not known whether olaparib is excreted in human milk. Women who are breastfeeding should talk to their doctor before taking olaparib.
The most commonly reported symptoms of acute overdose of olaparib are nausea, vomiting, and difficulty breathing. Patients who accidentally take too much olaparib should seek emergency medical attention immediately.
Inpoza Capsule 50 mg is contraindicated in patients with a known hypersensitivity to olaparib or any of the components of the tablet. Women who are pregnant or breastfeeding should not take olaparib.
Patients should take olaparib as prescribed by their doctor or pharmacist. The recommended dose is 400 mg, taken orally twice daily with a meal. Patients should not take more than the recommended dose. Patients should consult their doctor if they have any questions about how to take olaparib.
Inpoza Capsule 50 mg should be stored at room temperature, protected from light, and in a dry place. Patients should keep the medication in a sealed container and away from children or pets.
The volume of distribution of olaparib is approximately 160 L.
The half-life of olaparib is approximately 17 hours.
The clearance of olaparib is approximately 20 L/h.
See in details version Inpoza Capsule 50 mg also Inpoza Capsule 50 mg in bangla
Dr. Hasan Habibur Rahman
Pain, Arthritis, Paralysis, Sports Injury & Physical Medicine Specialist